Description: Living Cell Technologies Limited is a biotechnology company, which is engaged in discovering, developing and commercializing regenerative treatments, which use naturally occurring cells to restore function. The Company operates through the segment of research and development into living cell technologies, predominantly in New Zealand. Its product pipeline consists of cell therapies developed from cells sourced from a herd of disease-free pigs breed from stock originally discovered in the remote sub-Antarctic Auckland Islands. The Company's treatments are based on cell encapsulation and implantation for human therapeutics. The Company's products are NTCELL and DIABECELL. NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. DIABECELL is an insulin-producing cell product derived from pigs for the treatment of type I diabetes. It completed Phase I/IIa clinical trial for NTCELL for Parkinson's disease.
Home Page: www.lctglobal.com
LCT Technical Analysis
Columbia Funds Series Trust I
,
Phone:
61 3 8689 9997
Officers
| Name | Title |
|---|---|
| Dr. Bernard Tuch B.Sc., BSc, FRACP, GAICD, MBBS, MBBS (Hons), Ph.D. | Interim Chief Exec. Officer |
| Mr. Daya Uka | Chief Financial Officer |
| Dr. Belinda Di Bartolo | Chief Operations Officer |
| Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0971 |
| Price-to-Sales TTM: | 4907.395 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |